Allergan to buy Vitae Pharmaceuticals for $639m
Vitae discovers and develops small molecule drugs for diseases with significant unmet medical needs. The company uses its structure-based drug design platform, Contour, for discovering a portfolio of
Numab Therapeutics and Kaken Pharmaceutical have entered into a partnership and option agreement for the development of ND081, a multi-specific antibody designed as a potential first-in-class treatment for inflammatory bowel disease (IBD).
The combination of EPAM’s strong Big Data solutions practice and Sinequa’s unique Cognitive Search and Analytics platform offers customers the ability to gain quick, actionable insights from their